Description
Non-Fucosylated Anti-Human CCR4 (Mogamulizumab/) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; Solid Tumors; Advanced Solid Tumors; Gastric Cancer, Esophageal Cancer, Lung Cancer, Renal Cancer; Solid Tumor, Cancer, Carcinoma; Diffuse Large B-Cell Lymphoma, Recurrent and/ Refractory Hodgkin Lymphoma, Recurrent and/ Refractory Non-Hodgkin Lymphoma; Solid Tumor Cancer, Carcinoma, Hepatocellular Carcinoma; Advanced Solid Tumors, Metastatic Solid Tumors; Adult T-cell Leukemia-Lymphoma; Cutaneous T-Cell Lymphoma; HTLV-1 Associated Myelopathy;
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCR4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
C-C Motif Chemokine Receptor 4
Background
CCR4 (CC Motif Chemokine Receptor 4) is a Protein Coding gene.
Diseases associated with CCR4 include Cutaneous T Cell Lymphoma and Mycosis Fungoides.
Among its related pathways are Akt Signaling and Peptide ligandbinding receptors.
Gene Ontology (GO) annotations related to this gene include Gprotein coupled receptor activity and CC chemokine receptor activity.
An important paralog of this gene is CCR5.
Alternative Names
C-C Motif Chemokine Receptor 4, Chemokine (C-C Motif) Receptor 4, C-C CKR-4, CC-CKR-4, CMKBR4, CCR-4, K5-5, C-C Chemokine Receptor Type 4,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Mogamulizumab/
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; Solid Tumors; Advanced Solid Tumors; Gastric Cancer, Esophageal Cancer, Lung Cancer, Renal Cancer; Solid Tumor, Cancer, Carcinoma; Diffuse Large B-Cell Lymphoma, Recurrent and/ Refractory Hodgkin Lymphoma, Recurrent and/ Refractory Non-Hodgkin Lymphoma; Solid Tumor Cancer, Carcinoma, Hepatocellular Carcinoma; Advanced Solid Tumors, Metastatic Solid Tumors; Adult T-cell Leukemia-Lymphoma; Cutaneous T-Cell Lymphoma; HTLV-1 Associated Myelopathy;
